Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Dizal Updates Clinical News of its Two Global Trial Assets at ASCO

publication date: Jun 7, 2023

Shanghai Dizal presented new data for its two leading assets at the recent ASCO convention: sunvozertinib, a selective EGFR TKI targeting a wide spectrum of EGFR mutations, and golidocitinib, a JAK1 inhibitor. The company said sunvozertinib showed superior efficacy in treating advanced non-small cell lung cancer (NSCLC) and may prove to be Best-in-Class for NSCLC patients with EGFR Exon20ins mutations. The company has filed an NDA for Sunvozertinib in China. Golidocitinib showed promising tumor responses in relapsed or refractory peripheral T-cell lymphoma, an aggressive non-Hodgkin lymphoma. More details....

Stock Symbol: (SHA: 688192)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital